Horizon Pharma (HZNP) Getting Somewhat Favorable Media Coverage, Study Finds
Media coverage about Horizon Pharma (NASDAQ:HZNP) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.3805639078317 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune – GlobeNewswire (press release) (globenewswire.com)
- Horizon Pharma (HZNP) PT Set at $17.00 by Cantor Fitzgerald (americanbankingnews.com)
- Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments (finance.yahoo.com)
- What Does Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Share Price Indicate? (finance.yahoo.com)
Several research analysts have commented on HZNP shares. Jefferies Group boosted their target price on Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of Horizon Pharma in a research note on Sunday, October 22nd. ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Monday, October 16th. Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research downgraded Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $18.75.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same quarter in the prior year, the firm posted $0.70 earnings per share. The firm’s revenue was up 30.1% compared to the same quarter last year. analysts expect that Horizon Pharma will post 0.72 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/horizon-pharma-hznp-getting-somewhat-favorable-media-coverage-study-finds/1799191.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.